FUNDAMENTALS |
MarketCap: |
7.83 mill
|
EPS: |
-0.0400
|
P/E: |
-1.750
|
Earnings Date: |
Jun 12, 2024 |
SharesOutstanding: |
111.86 mill
|
Avg Daily Volume: |
0.0229 mill
|
RATINGS |
Rating CashFlow: |
Sell
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | n/a | n/a | n/a | n/a | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -1.750 | sector: PE -11.58
|
PE RATIO: COMPANY / INDUSTRY |
-0.35x
|
Company: PE -1.750 | industry: PE 4.94
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0580 - 0.0820
( +/- 17.14%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-08-01 | Rendall David | Buy | 125 000 | Stock Option (Right to Buy) |
2023-08-01 | Myers Thomas Richard | Buy | 150 000 | Stock Option (Right to Buy) |
2023-08-01 | Lee Tom Y | Buy | 125 000 | Stock Option (Right to Buy) |
2023-08-01 | Elliott Mark Stuart | Buy | 150 000 | Stock Option (Right to Buy) |
2023-08-01 | Chen Ivan | Buy | 150 000 | Stock Option (Right to Buy) |
INSIDER POWER |
100.00
|
Last
94 transactions |
Buy:
42 076 261 | Sell:
17 427 767 |
Forecast:
16:00 - $0.0700
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0700 (-11.39% )
|
Volume |
0.0015 mill
|
Avg. Vol. |
0.0229 mill
|
% of Avg. Vol |
6.32 %
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PURE
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.